TickerTalks
Browse all tickers →
TickerTalks›$IBRX
IBIBRX

ImmunityBio, Inc.

$IBRX·$8.8B·Biotechnology·Healthcare
$8.83+3.6%YTD+337.1%1Y+231.5%
Price updated 6h ago·X counts updated 2d ago
IBIBRX
$IBRXImmunityBio, Inc.
$8.83+3.64%676 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $IBRX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

676X posts · last 7 days
Sep 12Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $IBRX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 74% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data25 posts analyzed · as of 2026-09-29

ImmunityBio holders are firmly bullish on the ANKTIVA thesis, celebrating Dr. Soon-Shiong presenting 20 years of cancer-vaccine work to 170+ NIH/NCI professionals and pointing to a January 6 2027 PDUFA date for papillary-only NMIBC. The stock is up ~300% YTD; bulls frame 125M+ shares shorted against 65%-locked insider ownership as an inevitable squeeze setup, with only quiet worry about a possible triple-top pause.

Read what X is saying about $IBRX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $IBRX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-30

The move is getting stronger, with heavier trading behind it.

ImmunityBio is up 337% YTD on the ANKTIVA ramp with a January PDUFA in front of it — real product revenue, real short interest, real coiled spring.

ImmunityBio is the immunotherapy company built around IL-15 superagonist ANKTIVA, initially approved for BCG-unresponsive bladder cancer (NMIBC) and now working through a supplemental filing for the papillary-only patient group with a January 6, 2027 PDUFA date.

  • The product is finally in commercial ramp mode: Q1 revenue grew 167.6% YoY to $44M, after +425% and +407% the two prior quarters — this is a launch curve, not a science project.
  • The setup is structurally squeezed: 125M+ shares reported short against ~65% locked insider ownership (Soon-Shiong personally holds most of the float) — any positive PDUFA update runs into a very small available lend book.
  • The margin story is not there yet: -185% operating margin, PS 51x, still burning cash — so this is a bet on ANKTIVA label expansion and pipeline, not on next quarter's P&L.

Accelerating (65% of 52w range, above both moving averages), the Nov 3 print plus the January PDUFA sequence are the twin drivers. Continued ANKTIVA revenue acceleration extends the run; a soft ramp print or a PDUFA delay is what would test the +337% YTD gain.

Agrees with X sentimentBulls are right on the two things that matter — the January 6 PDUFA is a real, dated catalyst and the ~65% insider-locked float against 125M+ short is a genuine structural squeeze setup — and the quiet worry about a triple-top pause is the correct honest offset for a stock up 337% YTD. Both reads are on the same real setup.

What to watch: Q3 earnings Nov 3 and the January 6, 2027 papillary-NMIBC PDUFA sequence — continued ANKTIVA revenue acceleration extends the run; a soft ramp print or PDUFA delay tests the +337% YTD gain. Watch monthly script data as the leading indicator.

On the calendar: 2026-11-03 — Q3 earnings

Read the AI verdict on $IBRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IBRX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $IBRX

Partial — Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines.

Top industry ETF

$IBBiShares Biotechnology ETF
+24.4%YTD
+48.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-185%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
51.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
139%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
93.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.22$-0.08-175.0%
Q1 2026May 7, 2026$-0.62$-0.08-675.0%
Q4 2025Feb 23, 2026$-0.06$-0.08+25.0%
Q3 2025Nov 4, 2025$-0.07$-0.10+30.0%
Next earningsTue, Nov 3·consensus EPS $-0.08

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$44.2M+167.6%99.5%-158%$-0.62$-77.1M
Q4 FY25$38.3M+407.0%88.9%-169%$-0.06$-71.2M
Q3 FY25$32.1M+425.1%87.1%-174%$-0.07$-69.7M
Q2 FY25$26.4M+2423.9%99.5%-270%$-0.10$-80.8M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$225.6M$205.8M – $245.3M-$0.96-$0.99 – -$0.923
FY27$441.5M$252.5M – $630.4M-$0.14-$0.36 – $0.073
FY28$1.1B$766.2M – $1.4B$0.38$0.21 – $0.542
FY29$1.8B$1.3B – $2.5B$0.87$0.56 – $1.311
FY30$2.5B$1.8B – $3.5B$1.40$0.90 – $2.111

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.66%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+24.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Cheryl CohenDirector131.2K sh$1.2MSellJul 1Christobel SeleckyDirector159.5K sh$1.4MSellJun 30Christobel SeleckyDirector1.0K sh$9KSellJun 29Christobel SeleckyDirector95.7K sh$862KSellJun 24Barry J. SimonDirector25.0K sh$197KSellJun 4Barry J. SimonDirector23.0K sh$165K
+ 10 other (6 awards · 4 exempts) in window

See when $IBRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 6SC 13D/A
AI summary

Cambridge Equities, LP 2 Check the appropriate box if a membe amended its 13D filing disclosing a beneficial ownership position of 24.7% in IBRX (IBRX) as of 2026-08-06. The filer indicated plans: purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that sec. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

8-KPress release / Reg FDJul 308-K — Item 7.01: Press release / Reg FD
AI summary

IBRX (IBRX) filed an 8-K under Reg FD (Item 7.01) on 2026-07-30, posting a press release to its website or furnishing it to the SEC. On July 29, 2026, ImmunityBio, Inc. (“ImmunityBio” or the “Company”) issued a press release announcing that the Emirates Drug Establishment (“EDE”) of the United Arab Emirates (“UAE”) has granted marketing authorization for ANKTIVA ® across two indic This is an informational disclosure furnished (not filed) and does not create new liability under the Exchange Act. Materiality depends on the content of the presentation.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

ImmunityBio, Inc. held its 2026 Annual Meeting on June 9, 2026, with approximately 85% of outstanding shares represented. Stockholders re-elected all nine incumbent directors (including founder/CEO Patrick Soon-Shiong) and ratified Deloitte & Touche LLP as auditor for fiscal 2026. Routine governance for a founder-controlled company; high participation rate reflects institutional engagement.

8-KMaterial agreementMay 188-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

ImmunityBio, Inc. (IBRX) entered into an exclusive development and supply agreement with Japan BCG Laboratory (JBL) on May 14, 2026 for JBL to exclusively manufacture and supply the Tokyo-172 BCG strain for ImmunityBio's use in the U.S. and territories. ImmunityBio bears all development, clinical, and regulatory responsibilities for a 10-year initial term from FDA approval; no payments to JBL are due until approval, with at least 2 batches per year required post-approval. This agreement secures ImmunityBio's critical BCG supply chain ahead of anticipated commercial launch — a potentially material commercial enabler contingent on FDA approval.

8-KPress release / Reg FDApr 68-K — Item 7.01: Press release / Reg FD
AI summary

IBRX filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-06. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

+ 8 other (3 earnings 8-Ks · 2 10-Qs · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRXdefenseworld.net·6d agoImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?zacks.com·12d agoTidal Investments LLC Acquires New Stake in ImmunityBio, Inc. $IBRXdefenseworld.net·13d agoImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.20 Consensus Target Price from Brokeragesdefenseworld.net·14d agoWhy Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?zacks.com·27d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$VKTX$MRNA$RARE$NWBO$AURA$ARCT$NKTR$ABVX
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport